Press Release

Vetbiolix Announces Publication of Landmark Proof-of-Concept Clinical Study Results for VBX-1000 in Canine Periodontitis in *Frontiers in Veterinary Science*

- The manuscript has been accepted for publication in a peer-reviewed scientific journal: "*Frontiers in Veterinary Science*"

- The article is in open-access at *https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1656782/full*

Lille, Friday November 28th 2025 - Vetbiolix, a France-based veterinary biotechnology company and DeepTech France 2030 awardee, announces the publication of positive results from the Proof-of-Concept clinical study of its first-in-class drug candidate, VBX-1000, for canine periodontitis (VBX1200-CL-1001 POC study) in *Frontiers in Veterinary Science*, a leading peer-reviewed scientific journal. The publication demonstrates that VBX-1000 effectively reaches its molecular target, inhibits cathepsin-K activity, and promotes alveolar bone healing and regression of periodontitis. These results highlight the therapeutic potential of VBX-1000 as a safe approach for treating mild to moderate periodontitis in dogs and support its continued development in this indication.

Matthieu Dubruque, Managing Director of VETBIOLIX added: *This publication in an internationally recognized veterinary science journal with a peer-review process, validates VBX-1000 as the first veterinary drug candidate to promote alveolar bone healing in dogs with mild to moderate periodontitis. We believe that VBX-1000 has the potential to become a true groundbreaking disease modifier and VBX-1000 is now advancing through the development process to obtain regulatory approval. A double-blind, randomized, dose-ranging, placebo-controlled clinical trial in dogs suffering from periodontitis is being launched to confirm the potential of VBX-1000 in this indication.*»

About the *VBX1200-CL-1001 POC study*

The *VBX1200-CL-1001 POC study* was an open, multicenter, European study (France, Poland) seeking to evaluate the safety and efficacy of repeated oral administration of the drug candidate VBX-1000 for 90 days on different parameters of periodontal disease in dogs. This open-label clinical PoC study included a total of 20 dogs suffering from periodontal disease affecting at least three teeth. The primary objective of the study was achieved with a significant reduction ($p<0.001$) of the plasma marker of bone degradation: CTX1. A significant reduction ($p<0.05$) of the alveolar bone defect confirmed by two imaging techniques: Radiography and CBCT (Cone Beam Computed Tomography).

A significant improvement ($p<0.001$) in clinical measures of periodontal disease: CAL (Clinical Attachment Loss) and PPD (Periodontal Probing Depth).

About VBX-1000 and canine / feline periodontitis

VBX-1000 (also known as MIV-701) is a new, highly selective cathepsin K inhibitor. Previous tolerance studies have been performed in rats, dogs and monkeys, revealing no major safety concerns. VBX-1000 aims at promoting alveolar bone reformation in canine & feline periodontitis. VBX-1000 is currently in clinical development to obtain regulatory approval as the first veterinary disease-modifier treatment of periodontitis in companion animals, within a global pet oral care market is expected to reach 3,4 Bn$ by 2032.

About Vetbiolix – https://www.vetbiolix.com

Vetbiolix develops first-in-class clinical-stage drug candidates (oral small molecules) for the treatment of canine and feline periodontitis, osteoarthritis and intestinal motility disorders. Vetbiolix has built a unique pipeline of innovative drug candidates licensed (exclusive and worldwide license) from Human Health Biotech companies worldwide that will address unmet veterinary medical needs. Vetbiolix focuses exclusively on the clinical developments of its drug candidates and invests in (i) proof-of-concept clinical studies, (ii) CMC-Pharmaceutical developments, and (iii) regulatory clinical pilot and pivotal studies. The company's revenue generation will be based on sublicensing and/or co-development agreements with the veterinary pharmaceutical industry.

Contact: matthieu.dubruque@vetbiolix.com